Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Cat.No. : CSC-RO0178 Host Cell: K562
Size: >1x10^6 cells/vial Validation: T7 Endonuclease I assay
| Cat. No. | CSC-RO0178 |
| Description | K562-Cas9 cell line is engineered to stably overexpress Cas9 nuclease. The Cas9 nuclease in K562-Cas9 cell line has been functionally validated using T7 Endonuclease I assay. In combination with separately transfected sgRNAs, K562-Cas9 cell line can be used to efficiently generate targeted genomic modifications including gene knockout, gene knockin, gene mutagenesis, gene tagging etc. It is also an ideal cell line model for sgRNA screening and validation, either individually or in pools. |
| Introduction | Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology that contains two essential components: a guide RNA (gRNA) to match a target gene, and the Cas9 (CRISPR-associated protein 9) endonuclease which causes a double-stranded DNA break, allowing modifications to the genome via nonhomologous end joining (NHEJ) or homology-directed repair (HDR). |
| Target Gene | Cas9 |
| Host Cell | K562 |
| Host Cell Species | Homo sapiens (Human) |
| Product Type | Cas9 overexpression stable cell line |
| Applications | 1) CRISPR genome editing, such as gene knockout (KO), gene knockin (KI), gene mutagenesis, gene tagging etc. 2) High-throughput sgRNA screening and validation |
| Quality Control | 1) T7E1 assay 2) Mycoplasma detection |
| Size Form | One vial of frozen cells, typically >1x10^6 cells/vial |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Hemoglobinopathies are a set of hereditary genetic illnesses caused by mutations in the hemoglobin beta (HBB) gene. The researchers used a combined supramolecular nanoparticle (SMNP)/supramolecular nano substrate-mediated delivery (SNSMD) approach to enable CRISPR-Cas9 knockin of the hemoglobin beta (HBB) gene into the adeno-associated virus integration site 1 (AAVS1) safe-harbor site of an engineered K562 3.21 cell line carrying the sickle cell disease mutation. This required the successive delivery of SMNP vectors harboring a Cas9•sgRNA combination and an HBB/green fluorescent protein (GFP)-encoding plasmid. Successful CRISPR-Cas9 knockin by HDR was performed, and further in vivo investigations confirmed the proliferative capability of HBB/GFP-knockin K562 3.21 cells after intraperitoneal injection into mice, laying the framework for broad gene therapy applications in hemoglobinopathies.
Figure 1. The researchers employed a combined SMNP/SNSMD approach to deliver EGFP-Cas9•sgRNA or HBB/GFP plasmid into K562 3.21 cells. (Yang P, et al., 2020)
Accelerate your gene editing research! Creative Biogene's Cas9 stable cell line K562 provides you with a stable and efficient platform for CRISPR-Cas9 gene editing experiments. This advanced cell line ensures continuous expression of Cas9, eliminating the need for repeated transfections, simplifying the experimental process, and improving the accuracy and reproducibility of gene editing. Whether it is used for gene modification of disease models or gene therapy research, Cas9 stable cell line-K562 is an indispensable tool for you. Accelerate your research progress, choose Creative Biogene's Cas9 stable cell line K562, and start your innovative gene editing journey!
A: The Cas9 Stable Cell Line-K562 ensures the continuous activity of the Cas9 enzyme by integrating the CRISPR-Cas9 system encoded by the Cas9 gene into the genome of the K562 cell line, utilizing specific promoters and selection markers. This integration allows the cells to continuously produce functional Cas9 enzyme without relying on external Cas9 expression vectors.
A: The Cas9 Stable Cell Line-K562 provides a model for studying chronic myeloid leukemia (CML), particularly the function of the BCR-ABL fusion gene and targeted therapies. Through Cas9-mediated gene editing, scientists can simulate CML-associated gene mutations, leading to a better understanding of disease mechanisms and the development of new treatment strategies.
A: The application of the Cas9 Stable Cell Line-K562 in drug screening and development includes creating cell models with specific gene mutations to evaluate the therapeutic effects of potential drugs on CML cells. This cell line aids in accelerating the discovery and validation of new drugs, especially in the field of CML treatment.
A: The role of the Cas9 Stable Cell Line-K562 in studying gene expression regulation in CML cells is to investigate how the expression of specific genes affects the behavior of CML cells using Cas9-mediated gene editing technology. This helps reveal the molecular mechanisms of CML cells and provides information for developing new therapeutic targets.
A: The role of the Cas9 Stable Cell Line-K562 in studying drug resistance in CML cells is to simulate and investigate drug resistance-associated gene mutations through Cas9-mediated gene editing. This helps understand how CML cells develop resistance and how to develop strategies to overcome this resistance.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Cas9 Stable Cell Line-K562, with Cas9 stably integrated, allows researchers to immediately proceed with CRISPR/Cas9 gene editing, eliminating time spent on constructing and validating expression systems, greatly accelerating the initiation of experiments.
Canada
03/23/2022
Due to the stable expression of Cas9 protein in the Cas9 Stable Cell Line-K562, this cell line provides an efficient platform for gene knockout or knockin, making the study of gene functions and pathological mechanisms more efficient and accurate.
Germany
04/04/2020
The use of Cas9 Stable Cell Line-K562 simplifies the experimental workflow by eliminating the need for repeated verification of Cas9 protein expression, providing researchers with optimized and consistent experimental conditions, and reducing the risk of experimental failure.
United States
08/15/2020
The Cas9 Stable Cell Line-K562 becomes an essential tool in hematology and cancer research due to its suitability for a variety of gene editing applications, including disease model construction, functional genomics studies, etc.
Germany
06/04/2020
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.